|
Big Ten CRC News & Events
|
|
Investigators present kidney cancer study during ESMO
Big Ten Cancer Research Consortium investigators recently presented an E-Poster on the BTCRC-GU16-043 study during the ESMO 2020 Virtual Congress. The clinical trial is investigating whether adding guadecitabine, a drug that targets DNA methylation, might increase the proportion of patients with advanced clear cell renal cell carcinoma (ccRCC) who respond to treatment with durvalumab, a checkpoint-inhibitor drug that targets the PD-1/PD-L1 pathway. "In the past decade, checkpoint inhibitors have been a valuable addition to the therapeutic armamentarium of kidney cancer. However, not all patients benefit from this therapy, and there is an unmet need to further improve the clinical outcomes with novel combination strategies," said co-author Rohan Garje, MD, a genitourinary medical oncologist and researcher at the University of Iowa Carver College of Medicine and Holden Comprehensive Cancer Center.
|
|
BTCRC-GU15-067 tests liposomal irinotecan with FOLFOX in previously untreated pancreatic cancer
Researchers at Penn State University are conducting a multi-center phase II Big Ten Cancer Research Consortium study for adults with previously untreated, locally advanced pancreatic cancer that tests liposomal irinotecan in combination with FOLFOX, a chemotherapy regimen that includes oxaliplatin, leucovorin, and 5-fluorouracil. The study, led by Nelson S. Yee, MD, PhD, RPh, will determine the disease control rate of this combination - the percentage of patients whose tumors respond to treatment or remain stable. The study could help determine if this novel approach could be used as a first-line treatment for locally advanced pancreatic cancer.
|
|
Researchers study pembrolizumab and goserelin in advanced AR-positive salivary gland cancer
The phase II BTCRC-HN17-111 study is testing the combination of pembrolizumab with the androgen deprivation therapy goserelin for adults with advanced adrogen receptor-positive (AR+) salivary gland carcinoma. Salivary gland tumors are rare, with an incidence of approximately 2.5 to 3 cases per 100,000 annually in the Western world. "The objective of this study is to test the hypothesis that hormonal therapy with androgen deprivation therapy will increase the response rate to immunotherapy with pembrolizumab," said Manish Patel, DO, sponsor-investigator of the study and a medical oncologist at the University of Minnesota Department of Medicine, Division of Hematology, Oncology and Transplantation.
|
|
Joshi, Big Ten collaboration featured in Erie Times-News
Monika Joshi, MD, MRCP, Penn State Cancer Institute's representative on the Big Ten CRC Steering Committee and sponsor-investigator of Big Ten CRC studies, recently discussed the Big Ten Cancer Research Consortium in an interview with the Erie Times-News. "The idea was ... to build a forum so that people from member institutions can conduct collaborative research and clinical trials," Dr. Joshi said. "Research ideas are nurtured in working groups in which experts provide insights to design scientific and clinical trials. The consortium gives us access not only to experts in our field from different institutions, but also an immense amount of power from the Big Ten CRC administrative group."
|
|
Big Ten CRC investigators test gemtuzumab ozogamicin with venetoclax in relapsed/refractory acute myeloid leukemia
A phase Ib Big Ten Cancer Research Consortium multi-center study is testing the safety and efficacy of the monoclonal antibody gemtuzumab ozogamicin in combination with the BCL-2 inhibitor venetoclax in adults with relapsed or refractory AML. " Both drugs act to kill leukemia cells through induction of mitochondrial apoptosis; we believe that the combination therapy will be effective in these poor-prognosis AML patients," said John Quigley, MD, sponsor-investigator of the study and a hematologist at the University of Illinois Cancer Center. Secondary objectives include overall response rate, progression-free survival, event-free survival, and overall survival.
|
|
University of Wisconsin
Investigator Spotlight
Although gynecologic cancers are less common than breast cancer, the treatment of these cancers can be more challenging due to lack of effective screening and subsequent diagnosis at an advanced stage. New UW Carbone Cancer Center member Elisavet Paplomata, MD, an assistant professor in the Department of Medicine, brings extensive clinical research experience in studying both breast and gynecologic cancers to UW-Madison. Her work focuses on finding new drug treatment options for women diagnosed with these diseases.
Read more.
|
|
Integrative oncology training program accepting applications
Applications are now open for a nationwide integrative oncology training program. The Integrative Oncology Scholars Program at the University of Michigan is funded by a National Cancer Institute R25 grant. Eligible participants, include a multidisciplinary selection of physicians, physician assistants, nurses, psychologists, social workers, physical or occupational therapists, and pharmacists, who are actively engaged in clinical oncology practice.
|
|
Masonic Cancer Center launches survivorship research forum
In the past 10 years, cancer survivorship has matured into its own discipline addressing the complex and changing needs of the growing population of cancer survivors which now exceeds 17 million individuals in the United States alone. Cancer survivorship care requires innovative collaboration between experts from multiple healthcare disciplines that do not traditionally work together. Join the Masonic Cancer Center, University of Minnesota, for the inaugural Cancer Center Survivorship Research Forum as we explore the needs and care of cancer survivors, hear from expert clinicians and researchers, and network and collaborate in a hybrid format.
|
|
